Miller Anestesia

El sistema nervioso autónomo

Sección I

Fisiología y anestesia

256. Cleophas T, Kauw F: Pressor responses from non-

cardioselective beta-blockers. Angiology 39:587,

1988.

257. Strauss W, Parisi A: Combined use of calcium-chan-

nel and

-adrenergic blockers for the treatment of

chronic stable angina. Ann Intern Med 109:570,

1988.

258. Wayne VS, Harper RW, Laufer E, et al: Adverse inte-

raction between

-adrenergic blocking drugs and

verapamil: Report of three cases. Aust N Z J Med

12:285, 1982.

259. Pendleton RG, Newman DJ, Sherman SS, et al:

Effect of propranolol upon the hemoglobin-oxygen

dissociation curve. J Pharmacol Exp Ther 180:647,

1972.

260. Bernstein JS, Ebert TJ, Stowe DF, et al: Partial atte-

nuation of hemodynamic responses to rapid

sequence induction and intubation with labetalol.

J Clin Anesth 1:444, 1989.

261. Huey J, Thomas JP, Hendricks DR, et al: Clinical

evaluation of labetalol for the treatment of hyper-

tensive urgency. Am J Hypertens 1:284S, 1988.

262. Gabrielson G, Lingham R, Dimich I, et al: Compa-

rative study of labetalol and hydralazine in the

treatment of postoperative hypertension [abstract].

Anesth Analg 66:S63, 1987.

263. Skrobic J, Cruise C, Webster R, et al: Labetalol vs

nitroprusside in hypertension post coronary-bypass

surgery. Am J Hypertens 2:1295, 1989.

264. Lavies NG, Meiklejohn BH, May AE, et al: Hyper-

tensive and catecholamine response to tracheal

intubation in patients with pregnancy-induced

hypertension. Br J Anaesth 63:429, 1989.

265. Jouppilla P,Kirkinen P,Koivula A: Labetalol does not

alter the placental and fetal blood flow or maternal

prostanoids in pre-eclampsia. Br J Obstet Gynaecol

93:543, 1986.

266. Dupont AG, Van der Niepen P, Taeymans Y, et al:

Effect of carvedilol on ambulatory blood pressure,

renal hemodynamics,and cardiac function in essen-

tial hypertension. J Cardiovasc Pharmacol 10(Suppl

1):S130, 1987.

267. Eggertsen R, Sivertsson R,Adren L, et al: Haemody-

namic effects of carvedilol, a new

-adrenoceptor

blocker and precapillary vasodilator in essential

hypertension. J Hypertens 2:529, 1984.

268. Leonetti G, Sempieri L, Cuspidi C, et al, Resting and

postexercise hemodynamic effects of carvedilol, a

-adrenergic blocker and precapillary vasodilator

in hypertensive patients. J Cardiovasc Pharmacol

10(Suppl 1)1:S94, 1987.

269. Omvik P, Lund-Johansen P: Acute haemodynamic

effects of carvedilol in essential hypertension at

rest and during exercise. Eur Heart J 12:736,

1991.

270. Cervantes Escarcega JL, Ruiz de Chavez A, Guada-

lajara Boo J: Double-blind study of the efficacy and

tolerability of carvedilol vs nifedipine S.R. in

uncomplicated essential hypertension [in spanish].

Invest Med Int 19:142, 1992.

271. Ostergren J, Storstein L, Karlberg BE, et al: Quality

of life in hypertensive patients treated with either

carvedilol or enalapril. Blood Press 5:41, 1996.

272. Ruilope LM, Group CS: Comparison of a new vaso-

dilating beta blocker, carvedilol, with atenolol in the

treatment of mild to moderate essential hyperten-

sion. Am J Hypertens 7:129, 1994.

273. Weber K, Bohmeke T, van der Does R, et al: Com-

parison of the hemodynamic effects of metoprolol

and carvedilol in hypertensive patients. Cardiovasc

Drug Ther 10:113, 1996.

274. Albergati F, Paterno E, Venuti RP, et al: Comparison

of the effects of carvedilol and nifedipine in patients

with essential hypertension and non–insulin-

dependent diabetes mellitus. J Cardiovasc Pharma-

col 19(Suppl 1):S86, 1992.

275. Louis WJ, Krum H, Conway EL: A risk-benefit

assessment of carvedilol in the treatment of cardio-

vascular disorders. Drug Saf 11:86, 1994.

276. van der Does R, Eberhardt R, Derr I, et al: Effi-

cacy and safety of carvedilol in comparison with

nifedipine sustained-release in chronic stable

angina. J Cardiovasc Pharmacol 19(Suppl 1):S122,

1992.

277. Basu S, Senior R, van der Does R, et al: Carvedilol

reduces adverse cardiac events following acute myo-

cardial infarction [abstract]. Circulation 92(Suppl

1):1, 1995.

278. Senior R, Basu S, Lahiri A: Carvedilol prevents

remodeling and improves prognosis in patients with

left ventricular dysfunction following acute myocar-

dial infarction [abstract].JAmColl Cardiol 27(Suppl

A):319A, 1996.

279. Zehender M, Faber T, Schnabel P, et al: Benefits and

hazards of carvedilol in unstable angina: A double-

blind placebo controlled, randomized study [abs-

tract]. Circulation 92(Suppl 1):I, 1995.

280. Cohn JN, Fowler MB, Bristow MA, et al: Effect of

carvedilol in severe chronic heart failure [abstract].

J Am Coll Cardiol 27(Suppl A):169A, 1996.

281. Colucci WS, Packer M, Bristow MR, et al: Carvedilol

inhibits clinical progression in patients with mild

symptoms of heart failure. Circulation 94:2800,

1996.

282. Bristow MR, Gilbert EM,AbrahamWT, et al: Effects

of carvedilol on LV function and mortality in dia-

betic versus nondiabetic patients with ischemic or

nonischemic dilated cardiomyopathy [abstract].

Circulation 94(Suppl 1),I:3879, 1996.

283. Gray R, Bateman T, Czer L, et al: Comparison of

esmolol and nitroprusside for acute post–cardiac

surgical hypertension. Am J Cardiol 59:887,

1987.

284. Reves JG, Croughwell ND, Hawkins E, et al: Esmolol

for treatment of intraoperative tachycardia and/or

hypertension in patients having cardiac operations,

bolus loading technique. J Thorac Cardiovasc Surg

100:221, 1990.

285. Oxorn D, Knox JW, Hill J: Bolus doses of esmolol

for the prevention of perioperative hypertension

and tachycardia. Can J Anaesth 37:206, 1990.

286. Wallis DE, Littman WJ, Scanlon PJ: Safety and effi-

cacy of esmolol for unstable angina pectoris. Am J

Cardiol 62:1033, 1988.

287. Kirshenbaum JM, Kloner RJ, McGowan N, Antman

EM: Use of an ultrashort-acting

-receptor blocker

(esmolol) in patients with acute myocardial ische-

mia and relative contraindications to beta-blockade

therapy. J Am Coll Cardiol 12:773, 1988.

288. The Parkinson Study Group: Effect of deprenyl on

the progression of disability in early Parkinson’s

disease. N Engl J Med 3211364, 1989.

289. Roizen MF: Monoamine oxidase inhibitors: Are we

condemned to relive history, or is history no longer

relevant [letter]? J Clin Anesth 2:293, 1990.

290. Doyle DJ: Ketamine induction and monoamine

oxidase inhibitors. J Clin Anesth 2:324, 1990.

291. Materson BJ: Adverse effects of angiotensin-conver-

ting enzyme inhibitors in antihypertensive therapy

with focus on quinapril. Am J Cardiol 69:46C,

1992.

292. ISIS-4 (Fourth International Study of Infarct Survi-

val) Collaborative Group: A randomised factorial

trial assessing early oral captopril, oral mononitrate,

and intravenous magnesium sulphate in 58,050

patients with suspected acute myocardial infarction.

Lancet 345:669, 1995.

293. Nash DT: Comparative properties of angiotensin-

converting enzyme inhibitors: Relations with inhi-

bition of tissue angiotensin-converting enzyme and

potential clinical implications.Am J Cardiol 69:26C,

1992.

294. Raia JJ Jr, Barone JA, Byerly WG, Lacy CR: Angio-

tensin-converting enzyme inhibitors: A compara-

tive review. DICP 24:506, 1990.

295. Weber MA: Safety issues during antihypertensive

treatment with angiotensin converting enzyme

inhibitors. Am J Med 84(Suppl 4A):16, 1988.

296. Warner JN, Rush JE: Safety profiles of the angioten-

sin-converting enzyme inhibitors.Drugs 35(Suppl 5):

89, 1988.

297. Ferner RE: Adverse effects of angiotensin-conver-

ting-enzyme inhibitors. Adverse Drug React Acute

Poisoning Rev 141:528, 1990.

298. Jong P, Demers C, McKelvie RS, et al: Angiotensin

receptor blockers in heart failure: Meta-analysis of

randomized controlled trials. J Am Coll Cardiol

39:463, 2002.

299. Ziskind A: Transdermal scopolamine–induced psy-

chosis. Postgrad Med 84:73, 1988.

300. Wilkinson JA: Side-effects of transdermal scopola-

mine. J Emerg Med 5:389, 1987.

301. Gross NJ: Ipratroprium bromide. N Eng J Med

319:486, 1988.

302. Alcalay M, Izraeli S, Wallach-Kapon R, et al: Para-

doxical pharmacodynamic effect of atropine on

parasympathetic control: A study by spectral analy-

sis of heart rate fluctuations. Clin Pharmacol Ther

52:518, 1992.

303. Ghoneim MM, Dembo JB, Block RI: Time course of

antagonism of sedative and amnesic effects of dia-

zepam by flumazenil. Anesthesiology 70:899, 1989.

304. Charlson ME, MacKenzie CR, Gold JP: Preoperative

autonomic function abnormalities in patients with

diabetes mellitus and patients with hypertension.

J Am Coll Surg 179:1, 1994.

305. Ewing DJ, Martyn CN, Young RJ: The value of car-

diovascular autonomic function tests: 10 years expe-

rience in diabetes. Diabetes Care 8:491, 1985.

306. Esler M, Thompson J, Kaye D, et al: Effects of aging

on the responsiveness of the human cardiac sympa-

thetic nerves to stressors. Circulation 91:351, 1995.

307. Adams K: Current perspectives on

-receptor anta-

gonists in the treatment of symptomatic ventricular

dysfunction. Pharmacotherapy 16:69S, 1996.

308. Eichhorn EJ: Do

-blockers have a role in patients

with congestive heart failure? Cardiol Clin 12:133,

1994.

309. Rundqvist B, Eisenhofer G, Elam M, Friberg P: Atte-

nuated cardiac sympathetic responsiveness during

dynamic exercise in patients with heart failure. Cir-

culation 95:940, 1997.

310. Anand K, Hickey P: Halothane-morphine compa-

red with high dose sufentanil for anesthesia and

postoperative analgesia in neonatal cardiac surgery.

N Engl J Med 326:1, 1992.

311. Kehlet H: Manipulation of the metabolic response

in clinical practice. World J Surg 24:690, 2000.

312. Bardram L, Funch-Jensen P, Jensen P, et al: Recovery

after laparoscopic colonic surgery with epidural

analgesia, and early oral nutrition and mobilisation.

Lancet 345:763, 1995.

313. Wallace A, Galindez D, Salahieh A, et al: Effect of

clonidine on cardiovascular morbidity and morta-

lity after non-cardiac surgery. Anesthesiology

101:284, 2004.

314. Burgos LG, Ebert TJ, Asiddao C, et al: Increased

intraoperative cardiovascular morbidity in diabetics

with autonomic neuropathy.Anesthesiology 70:591,

1989.

315. Page MM,WatKins PJ: Cardiorespiratory arrest and

diabetic autonomic neuropathy. Lancet 1:14, 1978.

316. Ewing DJ, Clarke BF: Diagnosis and management of

diabetic autonomic neuropathy. BMJ 285:916, 1982.

317. Sato I, Hasegawa Y, Takahashi N, et al: Age-related

changes of cardiac control function in man. With

special reference to heart rate control at rest and

during exercise. J Gerontol 36:564, 1981.